US Edition
CMS (867.HK/8A8.SG) : New Drug for Renal Anaemia Desidustat Tablets Approved in China – Cloud PR Wire
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.4 Articles
4 Articles
CMS (867.HK/8A8.SG) : New Drug for Renal Anaemia Desidustat Tablets Approved in China – Chicago Headlines
SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that on 13 March 2026, new drug for renal anaemia Desidustat Tablets (the “Product”) has been approved for marketing in China by the National Medical Products Administration of the People’s Republic of China (NMPA). The Product is a novel, oral HypoxiaInducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in non-dialysis a…
CMS (867.HK/8A8.SG) : New Drug for Renal Anaemia Desidustat Tablets Approved in China – Cloud PR Wire
SHENZHEN, CHINA – China Medical System Holdings Limited (“CMS”, or the “Group”) is pleased to announce that on 13 March 2026, new drug for renal anaemia Desidustat Tablets (the “Product”) has been approved for marketing in China by the National Medical Products Administration of the People’s Republic of China (NMPA). The Product is a novel, oral HypoxiaInducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in non-dialysis a…
Shenzhen, March 13, 2026 – (Asia Pacific Business News via SeaPRwire.com) – Kangzhe Pharmaceutical Holdings Limited (867.HK/8A8.SG) (“Kangzhe Pharmaceutical”) is pleased to announce that its marketing authorization application for Dextromethorphan Tablets (formerly known as Dextromethorphan Tablets) (“the Product”), a novel drug for renal anemia, was approved by the National Medical Products Administration (NMPA) of China on March 13, 2026. The …
Shenzhen, March 13, 2026 – (Asia Pacific Business News via SeaPRwire.com) – Kangzhe Pharmaceutical Holdings Limited (867.HK/8A8.SG) (“Kangzhe Pharmaceutical”) is pleased to announce that its marketing authorization application for Dextromethorphan Tablets (formerly known as Dextromethorphan Tablets) (“the Product”), a novel drug for renal anemia, was approved by the National Medical Products Administration (NMPA) of China on March 13, 2026. The …
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
